Shopping Cart
- Remove All
- Your shopping cart is currently empty
Cixutumumab (IMC-A12) is a humanized IgG monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF1R). It has anticancer activity, inhibits ligand-dependent receptor activation and downstream signaling, and can be used in the study of non-small cell lung and prostate cancer.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $118 | In Stock | |
5 mg | $328 | In Stock | |
10 mg | $529 | In Stock | |
25 mg | $843 | In Stock | |
50 mg | $1,130 | In Stock |
Description | Cixutumumab (IMC-A12) is a humanized IgG monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF1R). It has anticancer activity, inhibits ligand-dependent receptor activation and downstream signaling, and can be used in the study of non-small cell lung and prostate cancer. |
In vitro | Cixutumumab showed significant growth inhibition of at least 50% in CHLA-9, TC-71 and Rh41 cell lines after 96 hours of treatment at concentrations ranging from 0.01 to 100 nM. [1] |
In vivo | In an in vivo model of the Pediatric Preclinical Testing Program (PPTP), Cixutumumab, given to rats by intraperitoneal injection at a dose of 1 mg twice weekly for six weeks, showed potent antitumor effects and significantly inhibited the progression of solid tumors. [1] |
Alias | NSC742460, NSC 742460, LY3012217, LY 3012217, IMC-A12, IMCA12 |
Cas No. | 947687-12-9 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.